Press Releases

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), and Life Science Consulting Pvt. Ltd., a reputed consulting and technology enabler to the life sciences industry, have partnered to provide best-in-class digital validation solutions to enhance compliance and quality across life sciences disciplines such as production, quality control and assurance, information technology, and research and development (R&D). Life Science Consulting

SGS is proud to announce that our Health Science laboratory based in Navi Mumbai has received the approval of the World Health Organization (Geneva) – Prequalification Unit (PQT) for testing, analytical services, and stability studies. The WHO-PQT approval marks a critical advancement in the company's ability to provide unparalleled support to pharmaceutical manufacturers worldwide in the development of high-quality pharmaceutical products.  SGS’s Health Science

Sun Pharmaceutical Industries Limited today announced that they have entered into a licensing agreement for commercializing Philogen's specialty product, Nidlegy™  in the territories of Europe, Australia and New Zealand. Nidlegy™, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by Philogen for the treatment of melanoma and non-melanoma skin cancers. Under the terms of the agreement, Sun Pharma will have exc

eMolecules, Inc., an industry leading chemical compound search-and-fulfillment platform for early discovery chemistry research, today announced the acquisition of Specs Compound Handling B.V. Specs offers chemical compound management services to the life sciences industry, particularly in the European pharmaceutical, biotechnology and academic sectors, driving time and cost efficiencies for customers’ large scale drug candidate screening programs.   Headquartere

The highly anticipated 9th edition of the PharmaLytica expo, a premier event in the pharmaceutical industry, is set to take place from June 1st till June 3rd 2023 at HITEX, Hyderabad. Organized by Informa Markets in India, PharmaLytica will bring together industry leaders, innovators, and stakeholders to explore the latest advancements and opportunities within India's thriving pharmaceutical industry. Spanning across an expansive 14,000 sqm of business space, the expo will showcase over 1

Bristol Myers Squibb today announced first results from the Phase 3 COMMANDS study, an open-label, randomized trial evaluating Reblozyl versus epoetin alfa, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia in adult patients with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) who require red blood cell (RBC) transfusions and are ESA-naïve. Results from the study will be featured as part of the press program at the American Society of Clinical On

Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen), today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor, have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexiadevelopment program (Librexia STROKE, Libr

The highly anticipated 9th edition of the PharmaLytica expo, a premier event in the pharmaceutical industry, is set to take place from June 1st till June 3rd 2023 at HITEX, Hyderabad. Organized by Informa Markets in India, PharmaLytica will bring together industry leaders, innovators, and stakeholders to explore the latest advancements and opportunities within India's thriving pharmaceutical industry. Spanning across an expansive 14,000 sqm of business space, the expo will showcase over 1

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into an exclusive partnership agreement regarding the supply and commercialization of five biosimilar candidates in Europe. Alvotech will be responsible for developme

Endo International plc  announced today that its subsidiary Endo Ventures Limited has executed an agreement with MAIA Pharmaceuticals, Inc. to distribute bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial in the U.S. Endo will commercialize the FDA-approved product through its Par Sterile Products business and expects to begin shipping in summer 2023. Hospital providers have told us what they need—ready-to-use medications that allow them to focus